Psychological Trauma, Post-Traumatic Stress Disorder, and Resilience in Adults With Congenital Heart Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDartmouth-Hitchcock Medical Center

About this trial

The purpose of this study, entitled "Psychological trauma, post-traumatic stress disorder, and resilience in adults with congenital heart disease in a large population sample", is to evaluate for exposures during a lifetime with congenital heart disease that may be associated with higher likelihood of developing PTSD.

Primary aim:

\- Identify individual patient characteristics (medical, psychosocial, socioeconomic, etc.) that are associated with a diagnosis of PTSD.

Secondary aims:

* Calculate the prevalence of those meeting PTSD criteria in the ACHD population using the "gold standard" diagnostic clinician interview, while using the same data to validate a PTSD screening self-report survey in the ACHD population. * Determine the role of resilience in ACHD patients using a validated screening survey to assess its protective role toward PTSD.

Hypotheses:

* There are certain exposures (e.g. post-surgical pain, ICU delirium, bullying due to CHD) that are associated with a higher incidence and odds of meeting PTSD criteria. * "Gold standard" diagnostic interviews will most accurately estimate the prevalence of PTSD in ACHD which has been overestimated on prior screening-based studies, although the scope of the problem is still great. * Patients with a higher resilience score will show an association with a lower risk of PTSD.

Eligibility criteria

Qualifiers

Congenital heart disease diagnosis, age >= 18 years

Enrolled in CHI registry

English proficiency for survey completion

Access to an internet connection. Can be via computer or handheld device.

Disqualifiers

Any who opt out

Age < 18 years

No diagnosis of congenital heart disease

Not enrolled in CHI registry/unable to access Internet

Trial design

Treatments tested in this trial

  • Other

Treatment groups

1,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

Dartmouth-Hitchcock Medical Center

Lead sponsor

Adult Congenital Heart Association

Collaborator